Financhill
Sell
23

CNCR Quote, Financials, Valuation and Earnings

Last price:
$11.96
Seasonality move :
-4.1%
Day range:
$11.91 - $12.43
52-week range:
$11.87 - $17.96
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2.4K
Avg. volume:
3.6K
1-year change:
-15.25%
Market cap:
--
Revenue:
--
EPS (TTM):
--

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CNCR
Range Cancer Therapeutics ETF
-- -- -- -- --
BBC
Virtus LifeSci Biotech Clinical Trials ETF
-- -- -- -- --
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
-- -- -- -- --
XHS
SPDR S&P Health Care Services ETF
-- -- -- -- --
XPH
SPDR S&P Pharmaceuticals ETF
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CNCR
Range Cancer Therapeutics ETF
$11.98 -- -- -- $0.00 0% --
BBC
Virtus LifeSci Biotech Clinical Trials ETF
$22.67 -- -- -- $0.24 1.06% --
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
$17.89 -- -- -- $0.00 0% --
XHS
SPDR S&P Health Care Services ETF
$92.97 -- -- -- $0.08 0.37% --
XPH
SPDR S&P Pharmaceuticals ETF
$42.72 -- -- -- $0.15 1.59% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CNCR
Range Cancer Therapeutics ETF
-- 1.903 -- --
BBC
Virtus LifeSci Biotech Clinical Trials ETF
-- 1.540 -- --
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
-- 1.221 -- --
XHS
SPDR S&P Health Care Services ETF
-- 1.543 -- --
XPH
SPDR S&P Pharmaceuticals ETF
-- 0.890 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CNCR
Range Cancer Therapeutics ETF
-- -- -- -- -- --
BBC
Virtus LifeSci Biotech Clinical Trials ETF
-- -- -- -- -- --
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
-- -- -- -- -- --
XHS
SPDR S&P Health Care Services ETF
-- -- -- -- -- --
XPH
SPDR S&P Pharmaceuticals ETF
-- -- -- -- -- --

Range Cancer Therapeutics ETF vs. Competitors

  • Which has Higher Returns CNCR or BBC?

    Virtus LifeSci Biotech Clinical Trials ETF has a net margin of -- compared to Range Cancer Therapeutics ETF's net margin of --. Range Cancer Therapeutics ETF's return on equity of -- beat Virtus LifeSci Biotech Clinical Trials ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CNCR
    Range Cancer Therapeutics ETF
    -- -- --
    BBC
    Virtus LifeSci Biotech Clinical Trials ETF
    -- -- --
  • What do Analysts Say About CNCR or BBC?

    Range Cancer Therapeutics ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Clinical Trials ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Range Cancer Therapeutics ETF has higher upside potential than Virtus LifeSci Biotech Clinical Trials ETF, analysts believe Range Cancer Therapeutics ETF is more attractive than Virtus LifeSci Biotech Clinical Trials ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    CNCR
    Range Cancer Therapeutics ETF
    0 0 0
    BBC
    Virtus LifeSci Biotech Clinical Trials ETF
    0 0 0
  • Is CNCR or BBC More Risky?

    Range Cancer Therapeutics ETF has a beta of 0.929, which suggesting that the stock is 7.096% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.042, suggesting its more volatile than the S&P 500 by 4.196%.

  • Which is a Better Dividend Stock CNCR or BBC?

    Range Cancer Therapeutics ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Virtus LifeSci Biotech Clinical Trials ETF offers a yield of 1.06% to investors and pays a quarterly dividend of $0.24 per share. Range Cancer Therapeutics ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Clinical Trials ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CNCR or BBC?

    Range Cancer Therapeutics ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues of --. Range Cancer Therapeutics ETF's net income of -- is lower than Virtus LifeSci Biotech Clinical Trials ETF's net income of --. Notably, Range Cancer Therapeutics ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Clinical Trials ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Range Cancer Therapeutics ETF is -- versus -- for Virtus LifeSci Biotech Clinical Trials ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CNCR
    Range Cancer Therapeutics ETF
    -- -- -- --
    BBC
    Virtus LifeSci Biotech Clinical Trials ETF
    -- -- -- --
  • Which has Higher Returns CNCR or EKG?

    First Trust Nasdaq Lux Digi Health Solutions ETF has a net margin of -- compared to Range Cancer Therapeutics ETF's net margin of --. Range Cancer Therapeutics ETF's return on equity of -- beat First Trust Nasdaq Lux Digi Health Solutions ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CNCR
    Range Cancer Therapeutics ETF
    -- -- --
    EKG
    First Trust Nasdaq Lux Digi Health Solutions ETF
    -- -- --
  • What do Analysts Say About CNCR or EKG?

    Range Cancer Therapeutics ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Lux Digi Health Solutions ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Range Cancer Therapeutics ETF has higher upside potential than First Trust Nasdaq Lux Digi Health Solutions ETF, analysts believe Range Cancer Therapeutics ETF is more attractive than First Trust Nasdaq Lux Digi Health Solutions ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    CNCR
    Range Cancer Therapeutics ETF
    0 0 0
    EKG
    First Trust Nasdaq Lux Digi Health Solutions ETF
    0 0 0
  • Is CNCR or EKG More Risky?

    Range Cancer Therapeutics ETF has a beta of 0.929, which suggesting that the stock is 7.096% less volatile than S&P 500. In comparison First Trust Nasdaq Lux Digi Health Solutions ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CNCR or EKG?

    Range Cancer Therapeutics ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. First Trust Nasdaq Lux Digi Health Solutions ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Range Cancer Therapeutics ETF pays -- of its earnings as a dividend. First Trust Nasdaq Lux Digi Health Solutions ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CNCR or EKG?

    Range Cancer Therapeutics ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Lux Digi Health Solutions ETF quarterly revenues of --. Range Cancer Therapeutics ETF's net income of -- is lower than First Trust Nasdaq Lux Digi Health Solutions ETF's net income of --. Notably, Range Cancer Therapeutics ETF's price-to-earnings ratio is -- while First Trust Nasdaq Lux Digi Health Solutions ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Range Cancer Therapeutics ETF is -- versus -- for First Trust Nasdaq Lux Digi Health Solutions ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CNCR
    Range Cancer Therapeutics ETF
    -- -- -- --
    EKG
    First Trust Nasdaq Lux Digi Health Solutions ETF
    -- -- -- --
  • Which has Higher Returns CNCR or XHS?

    SPDR S&P Health Care Services ETF has a net margin of -- compared to Range Cancer Therapeutics ETF's net margin of --. Range Cancer Therapeutics ETF's return on equity of -- beat SPDR S&P Health Care Services ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CNCR
    Range Cancer Therapeutics ETF
    -- -- --
    XHS
    SPDR S&P Health Care Services ETF
    -- -- --
  • What do Analysts Say About CNCR or XHS?

    Range Cancer Therapeutics ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Range Cancer Therapeutics ETF has higher upside potential than SPDR S&P Health Care Services ETF, analysts believe Range Cancer Therapeutics ETF is more attractive than SPDR S&P Health Care Services ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    CNCR
    Range Cancer Therapeutics ETF
    0 0 0
    XHS
    SPDR S&P Health Care Services ETF
    0 0 0
  • Is CNCR or XHS More Risky?

    Range Cancer Therapeutics ETF has a beta of 0.929, which suggesting that the stock is 7.096% less volatile than S&P 500. In comparison SPDR S&P Health Care Services ETF has a beta of 1.030, suggesting its more volatile than the S&P 500 by 2.997%.

  • Which is a Better Dividend Stock CNCR or XHS?

    Range Cancer Therapeutics ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SPDR S&P Health Care Services ETF offers a yield of 0.37% to investors and pays a quarterly dividend of $0.08 per share. Range Cancer Therapeutics ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CNCR or XHS?

    Range Cancer Therapeutics ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Services ETF quarterly revenues of --. Range Cancer Therapeutics ETF's net income of -- is lower than SPDR S&P Health Care Services ETF's net income of --. Notably, Range Cancer Therapeutics ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Range Cancer Therapeutics ETF is -- versus -- for SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CNCR
    Range Cancer Therapeutics ETF
    -- -- -- --
    XHS
    SPDR S&P Health Care Services ETF
    -- -- -- --
  • Which has Higher Returns CNCR or XPH?

    SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to Range Cancer Therapeutics ETF's net margin of --. Range Cancer Therapeutics ETF's return on equity of -- beat SPDR S&P Pharmaceuticals ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CNCR
    Range Cancer Therapeutics ETF
    -- -- --
    XPH
    SPDR S&P Pharmaceuticals ETF
    -- -- --
  • What do Analysts Say About CNCR or XPH?

    Range Cancer Therapeutics ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Range Cancer Therapeutics ETF has higher upside potential than SPDR S&P Pharmaceuticals ETF, analysts believe Range Cancer Therapeutics ETF is more attractive than SPDR S&P Pharmaceuticals ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    CNCR
    Range Cancer Therapeutics ETF
    0 0 0
    XPH
    SPDR S&P Pharmaceuticals ETF
    0 0 0
  • Is CNCR or XPH More Risky?

    Range Cancer Therapeutics ETF has a beta of 0.929, which suggesting that the stock is 7.096% less volatile than S&P 500. In comparison SPDR S&P Pharmaceuticals ETF has a beta of 0.757, suggesting its less volatile than the S&P 500 by 24.326%.

  • Which is a Better Dividend Stock CNCR or XPH?

    Range Cancer Therapeutics ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SPDR S&P Pharmaceuticals ETF offers a yield of 1.59% to investors and pays a quarterly dividend of $0.15 per share. Range Cancer Therapeutics ETF pays -- of its earnings as a dividend. SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CNCR or XPH?

    Range Cancer Therapeutics ETF quarterly revenues are --, which are smaller than SPDR S&P Pharmaceuticals ETF quarterly revenues of --. Range Cancer Therapeutics ETF's net income of -- is lower than SPDR S&P Pharmaceuticals ETF's net income of --. Notably, Range Cancer Therapeutics ETF's price-to-earnings ratio is -- while SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Range Cancer Therapeutics ETF is -- versus -- for SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CNCR
    Range Cancer Therapeutics ETF
    -- -- -- --
    XPH
    SPDR S&P Pharmaceuticals ETF
    -- -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is American Tower Stock Undervalued?
Is American Tower Stock Undervalued?

The market action of late has been nothing short of…

Is Broadcom Stock Overvalued?
Is Broadcom Stock Overvalued?

The semiconductor company Broadcom Inc. (NASDAQ:AVGO) is having a stellar…

4 Top Dividend Stocks to Buy Now
4 Top Dividend Stocks to Buy Now

If you’re looking for steady income, dividend stocks are a…

Stock Ideas

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 39x

Sell
47
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 114x

Sell
39
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 36x

Alerts

Buy
87
CEG alert for Jan 11

Constellation Energy [CEG] is up 25.15% over the past day.

Sell
1
MCY alert for Jan 11

Mercury General [MCY] is down 19.87% over the past day.

Buy
84
ATZAF alert for Jan 11

Aritzia [ATZAF] is up 17.63% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock